Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQUINT: Nivolumab plus Ipilimumab vs Platinum-Based Chemotherapy in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer
2016-004003-31Phase 2Completed
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in Pulmonary squamous cell carcinoma (2 arms), sponsored by Fondazione Ricerca Traslazionale. Primary endpoint: Progression-Free Survival rate at 12 months. Started Sep 2021; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2016-004003-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004003-31.